Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guthart and Gallagher grace Aragon board

This article was originally published in Scrip

Executive Summary

Leo Guthart, CEO of Topspin and founder and former CEO of Renaissance Technologies, has joined small-molecule drug discovery company Aragon Pharmaceuticals' board of directors following a $42 million series C financing round by Aragon in which Topspin was a lead investor (scripintelligence.com, 6 March 2012). In addition, Dr Carol Gallagher, previously president and CEO of Calistoga Pharmaceuticals before its acquisition by Gilead Sciences in April 2011, has joined the Aragon board as an independent director.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016528

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel